Access cutting-edge hodgkin lymphoma treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access hodgkin lymphoma specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hodgkin lymphoma treatment provided free
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 posi
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this hodgkin lymphoma clinical trial in Birmingham, AL
If you're searching for hodgkin lymphoma treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hodgkin lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.